Safety of parathyroid hormone for the treatment of osteoporosis

Current Osteoporosis Reports

Volumn 6, Issue 1, 2008, Pages 12-16

  Miller, Paul D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; URIC ACID; BONE DENSITY CONSERVATION AGENT;

ALKALINE PHOSPHATASE BLOOD LEVEL; CALCIUM EXCRETION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERURICEMIA; INCIDENCE; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; URIC ACID BLOOD LEVEL; ANIMAL; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; FISCHER 344 RAT; RAT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOPOROSIS; OSTEOSARCOMA; PARATHYROID HORMONE; RATS; RATS, INBRED F344; TERIPARATIDE;

EID: 44849091923     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0003-y     Document Type: Review

References (41)

1. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
2. Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
3. Saag KG, Shane E, Boonen S, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
4. Greenspan SL, Bone HG, Macciott TB, et al.: Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): Results from the TOP study. J Bone Miner Res 2005, 20(Suppl 1): S56.
5. Miller PD, Bilezikian JP, Deal C, Harris ST: Clinical use of teriparatide in the real world: Initial insights. Endocr Pract 2004, 10:139-148.
6. Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
7. Tashjian AH, Gagel RF: Teriparatide (human parathyroid hormone 1-34): two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006, 21:354-365.
8. Miller PD, Silverman S, Gold DT, et al.: Rationale, objectives, and design of the Direct Analysis of Nonvertebral fracture in the Community Experience (DANCE) study. Osteoporos Int 2006, 17:85-90.
9. Wagman R, Miller PD: The use of teriparatide and PTH (1-84) for the treatment of osteoporosis. Clin Rev Bone Mineral Metab 2006, 4:1-13.
10. Miller PD, Shergy WJ, Body JJ, et al.: Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005, 32:1556-1562.
11. Genant HK, Halse J, Briney WG, et al.: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005, 21:1027-1034.
12. Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: A meta-analysis. Osteoporos Int 2006, 17:273-280.
13. Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
14. McClung M, San Martin J, Miller PD, et al.: Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005, 165:1762-1768.
15. Chen P, Miller PD, Delmas PD, et al.: Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785-1790.
16. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal osteoporosis. J Bone Miner Res 2005, 20:962-970.
17. Chen P, Miller PD, Recker RR, et al.: Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22:1173-1180.
18. Dempster DW, Cosman F, Kurland AS, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
19. Jiang Y, Zhao J, Mitlak BH, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
20. Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
21. Dobnig H, Sipos AA, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
22. Parfitt AM: Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741-1743.
23. Bringhurst FR: Physiologic actions of PTH and PTHRP: II. Renal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:227-244.
24. Strewler GJ: Physiologic actions of PTH and PTHrP: I. Skeletal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:213-226.
25. Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 5. Edited by Favus MJ. Washington, DC: American Society for Bone and Mineral Research; 2006:230-235.
26. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995, 333:166-172.
27. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14-S19.
28. Holick M: Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
29. Heaney RP: The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005, 97:13-19.
30. Coe FL, Favus MJ, Crockett T, et al.: Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982, 72:25-32.
31. Heaney RP, Recker RR, Ryan RA: Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999, 9:13-18.
32. Bushinsky DA: Nephrolithiasis. J Am Soc Nephrol 1998, 9:917-924.
33. Miller PD, Bilezikian JP, Diaz-Curiel M, et al.: Occurrence of hypercalciuria in patients treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535-3541.
34. Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
35. Vahle JL, Long GG, Ma YL, Sato M: Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
36. Wilker CE, Jolette J, Smith SY, et al.: No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1-84) for 2 years: Role of the c-terminal PTH receptor? J Bone Miner Res 2004, 19(Suppl 1): S98.
37. Harper K, Krege JH, Marcus R, Mitlak BH: Osteosarcoma and teriparatide? J Bone Miner Res 2007, 22: 334.
38. Damron TA, Ward WG, Stewart A: Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007, 459:40-47.
39. Kalra S, Grimer RJ, Spooner D, et al.: Radiation-induced sarcoma of bone: Factors that determine outcome. J Bone Joint Surg Br 2007, 89:808-813.
40. Taghian A, de Vathaire F, Terrier P, et al.: Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991, 21:361-367.
41. Kirova YM, Vilcoq JR, Asselain B, et al.: Radiationinduced sarcomas after radiotherapy for breast carcinoma: A large-scale, single institution review. Cancer 2005, 104:856-863.